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ABSTRACT
Background Immune checkpoint inhibitors (ICIs) have 
produced signiicant survival beneit across many 
tumor types. However, immune- related adverse events 
are common including autoimmune responses against 
different endocrine organs. Here, a case of ICI- mediated 
hypoparathyroidism focusing on long- term follow- up and 
insights into its etiology is presented.
Case and methods A 73- year- old man developed 
severe symptomatic hypocalcemia after the initiation 
of ipilimumab and nivolumab for the treatment of 
metastatic melanoma. Hypoparathyroidism was diagnosed 
with undetectable intact parathyroid hormone (PTH). 
Immunoprecipitation assays, ELISAs, and cell- based 
functional assays were used to test the patient for 
antibodies against the calcium- sensing receptor (CaSR). 
NACHT leucine- rich repeat protein 5 (NALP5) and cytokine 
antibodies were measured in radioligand binding assays 
and ELISAs, respectively.
Results The patient’s symptoms improved with aggressive 
calcium and vitamin D supplementation. At 3 years and 
3 months since the diagnosis of hypoparathyroidism, PTH 
was still inappropriately low at 7.6 pg/mL, and attempted 
discontinuation of calcium and calcitriol resulted in 
recurrent symptomatic hypocalcemia. Analysis for an 
autoimmune etiology of the patient’s hypoparathyroidism 
indicated that CaSR antibodies were negative before 
treatment and detected at multiple time points afterwards, 
and corresponded to the patient’s clinical course of 
hypoparathyroidism. CaSR antibodies puriied from the 
patient’s serum activated the human CaSR. The patient was 
seronegative for NALP5 and cytokine antibodies, indicating 
that their hypoparathyroidism was not a manifestation of 
autoimmune polyendocrine syndrome type 1.
Conclusion The etiology of hypocalcemia is likely 
autoimmune hypoparathyroidism caused by the 
development of CaSR- activating antibodies that might 
prevent PTH release from the parathyroid.
BACKGROUND
Monoclonal antibodies that inhibit 
immune checkpoint proteins such as the 
cytotoxic T lymphocyte antigen-4 (CTLA-4) 
and programmed cell death 1 receptor (PD-1) 
have revolutionized the treatment approach 
to many solid tumors.1 2 Furthermore, the 
combination of ipilimumab, an anti- CTLA-4 
antibody, and nivolumab, a PD-1 inhibitor, 
has demonstrated synergistic antitumor 
activities, significantly improving objective 
response rates and overall survival in patients 
with advanced melanoma or renal cell carci-
noma.3 4 Given these results, we expect the 
number of emerging indications for immune 
checkpoint inhibitors (ICIs) to continue to 
grow. However, these novel agents can cause 
life- threatening immune- related adverse 
events (irAEs) since checkpoint blockade 
can lead to unrestrained immune attack on 
healthy tissues.5 In addition to the skin and 
the gastrointestinal tract, the endocrine 
system is one of the most commonly affected 
organs.5 6
Thyroid dysfunction and hypophysitis have 
the highest incidence among the endocrine 
irAEs of ICIs.5 6 Thyroid disorders are more 
common with the anti- PD-1/programmed 
cell death receptor ligand 1 antibodies, 
either as monotherapy or in combination 
with an anti- CTLA-4 antibody.7 8 Hypophysitis 
is more frequently observed with ipilimumab 
as single agent or in combination with other 
ICIs.5 Rare cases of type 1 diabetes, Graves’ 
ophthalmopathy, and autoimmune adrenal-
itis have been observed.5 6 Hypoparathy-
roidism is exceedingly rare.9–11
Here, we describe the long- term follow- up 
of a patient who developed severe symptom-
atic hypocalcemia after the initiation of ipili-
mumab and nivolumab combination for the 
treatment of metastatic melanoma. A possible 
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Figure 1 Time course of biochemical tests. The results 
of biochemical tests are shown for corrected calcium 
(normal range: 8.4–10.2 mg/dL), phosphate (normal range: 
2.5–4.5 mg/dL), ionized calcium (normal range: 1.13–
1.32 mmol/L), magnesium (normal range: 1.8–2.9 mg/dL), and 
intact parathyroid hormone (PTH) (normal range: 15–65 pg/
mL) from the start of acute hypocalcemia to the most recent 
follow- up visit.
autoimmune etiology of the patient’s hypoparathyroidism 
was investigated. The patient’s serum samples were tested 
for: (1) Calcium- sensing receptor (CaSR) antibodies, 
as they can be present in patients with hypoparathy-
roidism.12–14 (2) NACHT leucine- rich repeat protein 5 
(NALP5) antibodies, as they can be indicative of hypo-
parathyroidism in the context of autoimmune polyendo-
crine syndrome type 1 (APS1).15 (3) Cytokine antibodies 
to confirm or deny a diagnosis of APS1 of which hypo-
parathyroidism is a key manifestation.16 The effect of the 
patient’s CaSR antibodies on CaSR activity was also tested.
CASE PRESENTATION
A 73- year- old man with widely metastatic BRAF V600K 
mutated melanoma was treated in the frontline setting 
with ipilimumab 3 mg/kg plus nivolumab 1 mg/kg 
combination therapy intravenously every 3 weeks. One 
week after his second cycle, he presented to the emer-
gency department with increased fatigue, dizziness, diffi-
culty maintaining balance, and abdominal bloating and 
discomfort. His wife also noticed slowing of speech and 
change in facial expression. Review of systems was posi-
tive for perioral numbness, paresthesia in both hands and 
feet, and numbness over his left abdomen. Physical exam 
was remarkable for marked ataxia when walking.
Laboratory tests at presentation revealed a low total 
calcium of 5 mg/dL (normal range: 8.4–10.2 mg/dL), 
low ionized calcium of 0.67 mmol/L (normal range: 
1.13–1.32 mmol/L), high phosphate of 6.6 mg/dL 
(normal range: 2.5–4.5 mg/dL), low magnesium of 
1.5 mg/dL (normal range: 1.8–2.9 mg/dL), and unde-
tectable intact parathyroid hormone (PTH) at <1 pg/mL 
(normal range: 15–65 pg/mL) (figure 1). In addition, 
the patient had normal albumin of 4.1 g/dL (normal 
range: 3.5–5.2 g/dL), normal creatinine of 0.9 mg/dL 
(normal range: 0.67–1.17 mg/dL), but a high urinary 
calcium of 266.6 mg/24 hours. The patient also had 
low 25- hydroxyvitamin D of 18 ng/mL (normal range: 
30–100 ng/mL) and normal 1,25- dihydroxyvitamin 
D of 29 pg/mL (normal range: 18–64 pg/mL). The 
1,25- dihydroxyvitamin D level would be expected to be 
low because of severely reduced PTH. It is likely that 
the hypoparathyroidism event was acute such that 1,25 
dihydroxyvitamin D was still normal, although low, at 
the point of presentation. The laboratory analyses led to 
a diagnosis of severe symptomatic hypocalcemia due to 
primary hypoparathyroidism.
The patient was initiated on a calcium gluconate drip 
(5000 mg/500 mL calcium gluconate with 5% dextrose at 
an infusion rate of 50 mL/hour), oral calcium carbonate 
supplement (equivalent to 1500 mg of elemental calcium 
three times daily), calcitriol (0.5 µg twice daily), and ergo-
calciferol (50 000 IU daily for 5 days and weekly, there-
after). Mild hypomagnesemia was corrected (figure 1). 
Despite normalization of calcium and magnesium levels, 
PTH remained undetectable (figure 1). Nevertheless, 
the patient’s symptoms improved in parallel with serum 
calcium normalization. He was discharged 4 days later 
on calcium carbonate (equivalent of 1000 mg elemental 
calcium twice daily), calcitriol (0.25 µg twice daily) and 
ergocalciferol (50 000 IU weekly).
The patient received cycle 3 of ipilimumab and 
nivolumab therapy 3 weeks later. Additional irAEs 
emerged including thyroiditis with a thyrotoxicosis phase 
(free T4 of 4.52 ng/mL, normal range: 0.93–1.70 ng/
mL; thyroid- stimulating hormone (TSH) of <0.02 µU/
mL, normal range: 0.27–4.20 µU/mL; total T3 of 226 ng/
dL, normal range 80–200 ng/dL; thyroid peroxidase 
antibody- negative, and TSH receptor antibody- negative), 
and hepatitis (alanine aminotransferase of 706 U/L, 
normal range: 7–56 U/L; aspartate aminotransferase of 
447 U/L, normal range: 14–46 U/L) requiring high doses 
of steroids and permanent discontinuation of ICI therapy 
4 weeks after the hypoparathyroidism diagnosis.
Despite his toxicities, the patient achieved a complete 
response to treatment with disappearance of all his meta-
static tumors and remains in remission and asymptomatic 
from his previous irAEs almost 2 years later (figure 2). His 
calcium level continued to be stable, between 8.0 mg/
dL and 8.5 mg/dL (figure 1) with low doses of calcium 
(equivalent of 1000 mg elemental calcium per day), 
calcitriol (0.25 µg daily) and ergocalciferol (50 000 IU 
weekly). PTH remained undetectable (<0.1 pg/mL) for 
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Figure 2 Response of the patient to ipilimumab plus 
nivolumab treatment. Positron emission tomography (PET) 
scans showing the patient prior to treatment (left- hand panel) 
and the complete response to treatment (right- hand panel) 
with disappearance of all the patient’s cancer lesions 2 years 
after the start of immune checkpoint inhibitor (ICI) therapy.
Figure 3 Calcium- sensing receptor (Casr) and NACHT 
leucine- rich repeat protein 5 (NALP5) antibody tests. The 
upper limit of healthy control sera in the CaSR antibody 
assay was a CaSR antibody index of 2.69. The upper limit 
of healthy control sera in the NALP5 antibody assay was an 
NALP5 antibody index of 1.73. The upper limit for each assay 
is shown by a dotted line.
over 2 years (figure 1). However, 2 years and 3 months 
since this sentinel event, his PTH level was 12.8 pg/mL 
with a corrected calcium of 8.2 mg/dL (figure 1). A trial 
of calcium and calcitriol discontinuation was attempted, 
however, the patient developed recurrent symptoms 
of hypocalcemia and, therefore, was given calcium and 
calcitriol. At his last follow- up at 3 years and 3 months, his 
PTH was again inappropriately low at 7.6 pg/mL.
With respect to the etiology of the patient’s hypopara-
thyroidism, he denied a history of past radiation to the 
neck or prior surgery to thyroid and parathyroid glands 
which could have damaged the organs prior to ICI treat-
ment. No familial hypocalcemic disorders were present. 
The patient had no history of autoimmune disease or 
parathyroid inflammation. In addition, the patient’s 
total calcium level prior to immunotherapy initiation 
was normal at 9.2 mg/dL. This information excluded the 
possibility that he had a primary parathyroid dysfunction 
prior to treatment with ICIs. The patient’s hypoparathy-
roidism was therefore considered to be related to his 
treatment with ipilimumab and nivolumab and that it 
maybe autoimmune in etiology as irAEs against endo-
crine organs often are.
Autoimmune hypoparathyroidism can occur in isola-
tion or as part of Autoimmune Polyglandular Syndrome 
Type 1 (APS1).12 14 Initially, to eliminate APS1 as the 
disease context for the patient’s hypoparathyroidism, 
serial archived serum samples from the patient were evalu-
ated in ELISAs for cytokine antibodies against interleukin 
(IL) 22, IL- 17F, IL- 17A, interferon (IFN)-ω, IFN-α2A, 
and IFN-λ1.16 These are disease markers for APS1. The 
patient was negative for all cytokine antibodies tested, 
indicating that the patient was unlikely to have APS1. In 
addition, serum samples were investigated using radioli-
gand binding assays for the APS1 hypoparathyroidism 
markers, NALP5 antibodies.15 However, NALP5 antibody 
serology was negative at all time points (figure 3).
Antibodies against the CaSR have been detected in 
patients with autoimmune hypoparathyroidism with and 
without the context of APS1.12–14 17 In the present case, 
CaSR antibodies were detected at multiple time points, 
with time at positivity correlating with the patient’s clin-
ical course of hypoparathyroidism (figure 3). His serum 
samples were negative for CaSR antibodies at two time 
points prior to hypoparathyroidism diagnosis, and 
increased at the time of hypoparathyroidism diagnosis 
and remained high during follow- up.
Patient serum samples post- ICI therapy were analyzed 
in ELISAs using CaSR peptides spanning amino acids 
41–69, 75–115, 114–126, 138–170, 171–195, 214–238, 
260–340, 344–358, and 374–391 as the target antigens.13 
The results indicated that the patient’s CaSR antibodies 
were against the CaSR peptide 114–126, an epitope previ-
ously identified.13 No other CaSR antibody- binding spec-
ificities were detected (figure 4A). Subsequently, peptide 
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Figure 4 Characterization of the patient’s calcium- sensing 
receptor (CaSR) antibodies. (A) Epitope identiication. Patient 
post- treatment serum samples and sera from 10 healthy 
controls were evaluated at a dilution of 1:100 in ELISAs for 
antibodies against CaSR peptides 41–69, 75–115, 114–126, 
138–170, 171–195, 214–238, 260–340, 344–358, and 
374–391. The CaSR antibody index (mean±SD) is shown 
for three experiments. (B) Effect of the patient’s CaSR 
antibodies on CaSR activity. Changes in inositol-1- phosphate 
(IP1) accumulation were measured in response to Ca2+ in 
human embryonic kidney 293 cells expressing the receptor 
(HEK293- CaSR) cells preincubated with the patient’s puriied 
CaSR antibody against CaSR peptide 114–126 at a 1:100 
dilution prior to stimulation with Ca2+ at a inal concentration 
of 1.5 mM. HEK293- CaSR cells without preincubation with 
antibody and preincubated with IgG from a healthy individual 
were included as controls. Intracellular IP1 accumulation 
was measured using a IP- One ELISA. The mean (±SD) IP1 
accumulation is shown for three experiments.
affinity chromatography13 was used to purify CaSR anti-
bodies against CaSR peptide 114–126 from the patient’s 
serum.
In some cases, CaSR antibodies have been shown to 
modulate the receptor’s function such that its response 
to calcium is adversely affected.14 17 To determine 
the effects of the patient’s CaSR antibodies on CaSR 
function, human embryonic kidney 293 cells expressing 
the receptor (HEK293- CaSR) were preincubated with the 
patient’s purified CaSR antibodies prior to measurement 
of Ca2+- induced inositol-1- phosphate (IP1) accumulation 
in an IP- One ELISA.17 The results showed that prein-
cubation of HEK293- CaSR cells with the patient’s CaSR 
antibody significantly increased the levels of IP1 accumu-
lation when compared with Ca2+- stimulation of HEK293- 
CaSR cells that were not preincubated with CaSR antibody 
(figure 4B). The results indicated that the patient’s CaSR 
antibodies were able to stimulate the receptor so that 
even at lower than optimum calcium levels PTH secre-
tion from the parathyroids would be reduced leading to 
hypocalcemia.
DISCUSSION
Chronic hypoparathyroidism is a rare endocrinopathy.18 
Surgical intervention to the neck is responsible for 75% 
of cases with the remainder occurring secondary to auto-
immune, genetic, or infiltrative etiologies.18 19 Autoim-
mune hypoparathyroidism is more commonly seen as 
part of APS1, but can arise as an isolated disease.19 20 It 
can be caused by immune- mediated damage to the para-
thyroid gland or by functional hypoparathyroidism due 
to antibody- induced activation of parathyroid func-
tion.14 17 20 Such activating antibodies are directed towards 
the CaSR.14 By decreasing the receptor’s set point, PTH 
is not released at lower than optimum blood calcium 
concentrations resulting in hypocalcemia.14 20 Although 
rare, autoimmune hypoparathyroidism can also manifest 
following the use of ICIs for the treatment of cancer.9–11
Here, we report a patient with metastatic melanoma 
who developed hypocalcemia resulting from autoim-
mune hypoparathyroidism following ICI treatment. The 
case described demonstrates a cause of hypoparathy-
roidism that is likely immune- mediated secondary to ICIs, 
given the temporal proximity of hypoparathyroidism to 
the initiation of treatment without other mechanism for 
acute injury to the parathyroid glands. The detection of 
CaSR- activating antibodies matching the patient’s clin-
ical course further supports a diagnosis of autoimmune 
hypoparathyroidism caused by the development of CaSR 
antibodies that could inhibit PTH release from the para-
thyroid even at below optimum levels of blood calcium.14
A similar case of hypoparathyroidism in the setting of 
ICIs has been reported. Piranavan et al described a case 
with similar clinical presentation and development of 
CaSR antibodies.10 In that case also, antibody- activation 
of the CaSR was demonstrated by increased intracellular 
IP1 levels in a CaSR- expressing cell line following treat-
ment with the patient’s IgG. In our case, we were able 
to confirm that the patient had negative CaSR antibodies 
before their hypoparathyroidism diagnosis and to demon-
strate that the patient became CaSR antibody- positive at 
the time of hypoparathyroidism diagnosis and remained 
so with long- term follow- up. Hypoparathyroidism appears 
to be a long- term sequela, however, so continuous 
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follow- up is needed to assess possible recovery, although 
this is challenging for patients with advanced malignan-
cies who have received ICIs late in their disease course.
While T cell- mediated immune destruction of healthy 
tissue is typically considered the overarching mechanism for 
irAEs associated with ICIs,21 22 it is increasingly appreciated 
that humoral immunity may play a role in their develop-
ment. Some irAEs such as hypothyroidism, bullous pemphi-
goid, myasthenia gravis, and nephritis have been observed 
with similar autoantibody profiles traditionally associated 
with their autoimmune disease counterparts.7 23–25
Seronegative antibody- mediated irAEs have also been 
described with ICIs. Wilson et al reported novel IgG 
and IgM reacting to relevant tissue preparations in a 
patient with seronegative transverse myelitis secondary 
to pembrolizumab and another with seronegative myas-
thenia gravis due to ipilimumab- nivolumab admin-
istration,26 suggesting that ICIs uncover previously 
unrecognized autoreactive antibodies. This is corrob-
orated by Gowen et al, demonstrating that patients who 
later developed severe irAEs to ICIs possessed a distinct 
pretreatment antibody pattern extending beyond the 
known autoantibodies, such as antinuclear, antismooth 
muscle, and antithyroid antibodies.27
Recently, Das et al showed that combined ICIs led to 
a decrease in circulating B cells, an increase in CD21 B 
cells, and an increase in plasmablasts after the first cycle 
of therapy.28 More importantly, the magnitude of early B 
cell changes correlated with both the time to onset and 
the grade of subsequent irAEs, and the patient cohort 
with early B cell changes had much higher rates of grade 
3 or higher irAEs at 6 months. The use of anti- CD20 anti-
bodies in the management of irAEs from ICIs has also 
been reported.29 Altogether, this evidence supports the 
notion of a B cell- mediated mechanism for irAEs that 
exists alongside the T cell- dependent model. It remains 
unclear whether B cell and antibody changes represent 
the direct impact of ICIs or the indirect effect of self- 
tolerance dysregulation secondary to ICIs or both.
In conclusion, hypoparathyroidism is a rare but life- 
threatening endocrinopathy associated with ICIs. Thus, 
calcium levels should be monitored during treatment. 
The underlying mechanism of ICI- related hypoparathy-
roidism likely involves the formation of CaSR- activating 
antibodies. Investigation into the B cell compartment may 
allow for a better understanding of irAEs pathophysiology 
and open new avenues for identifying patient subsets at 
high risk for irAEs and for developing novel treatment 
options for these.
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